article thumbnail

Anocca signs licensing deal for EmendoBio’s gene-editing tech

Pharmaceutical Technology

Anocca has entered a licensing agreement with EmendoBio for the use of the latter’s OMNI-A4 nuclease, a gene editing technology.

article thumbnail

Moderna ends gene editing alliance with Metagenomi

Bio Pharma Dive

Metagenomi said the companies’ decision to part ways followed a “strategic prioritization” undertaken by Moderna, which has made several investments in gene editing research in recent years.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA approves Vertex’s gene-edited therapy for beta thalassemia

Pharmaceutical Technology

The US FDA has approved Vertex's CASGEVY, a gene-edited cell therapy, to treat transfusion-dependent beta thalassemia.

article thumbnail

Sanofi expands research deal with gene editing startup Scribe

Bio Pharma Dive

Scribe will receive $40 million upfront from Sanofi in a collaboration initially focused on developing an in vivo gene editing treatment for sickle cell disease.

article thumbnail

Regeneron and Mammoth team up to develop gene editing therapies

Pharmaceutical Technology

Regeneron Pharmaceuticals has collaborated with Mammoth Biosciences to develop in vivo clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapies.

article thumbnail

Pfizer expands into gene editing with Beam research deal

Bio Pharma Dive

Pfizer's work with mRNA vaccines led it explore other applications of the technology, resulting in a multi-year partnership with the high-profile biotech Beam Therapeutics on gene editing treatments for rare diseases.

article thumbnail

Gene editing biotech Homology hits reset and seeks a sale

Bio Pharma Dive

The company will lay off 87% of its workforce and halt further research, including for a gene editing therapy to treat the rare disease PKU.